Effectiveness, Acceptability and Safety of Pharmaceutical Management for Combat-Related PTSD in Adults Based on Systematic Review of Twenty-Two Randomized Controlled Trials

Jin-Zhu Yan†, Jia-Ling Liu†, Xiao-Zheng Li, Zhi-Xin Zhang, Run-Ben Liu, Chao Zhang and Qin-Qin Gong

Department of Obstetrics, Taihe Hospital, Hubei University of Medicine, Shiyan, China, Center for Evidence-Based Medicine and Clinical Research, Taihe Hospital, Hubei University of Medicine, Shiyan, China, Center of Women’s Health Sciences, Taihe Hospital, Hubei University of Medicine, Shiyan, China

Objective: This study assessed the efficacy, acceptability, and safety of pharmaceutical management for combat-related post-traumatic stress disorder (PTSD) to provide a clinical decision-making basis for clinicians.

Method: A comprehensive search was conducted using Ovid MEDLINE, Ovid EMBASE, Cochrane Library, Scopus, ScienceDirect, and Web of Science for randomized controlled trails (RCTs), which reported pharmaceutical management and placebo for adults with combat-related PTSD, that were published until April 21, 2021. The effectiveness, acceptability, and adverse events (AEs), were designed as interested outcomes. The change in total symptoms of combat-related PTSD according to the clinician rating scale was defined as primary outcome, and the others were defined as secondary outcomes.

Results: Twenty-two RCTs with 1,221 patients were involved. Compared with placebo, overall active comparators had statistical differences for all outcomes, including the change in total symptoms of combat-related PTSD [SMD = −0.36, 95%CI (−0.62, −0.09)], depression [SMD = −0.28, 95%CI (−0.45, −0.10)], anxiety [SMD = −0.44, 95%CI (−0.64, −0.23)], re-experience [SMD = −0.33, 95%CI (−0.52, −0.13)], avoidance [SMD = −0.24, 95%CI (−0.43, −0.05)], and hyper-arousal [SMD = −0.26, 95%CI (−0.48, −0.03)]. Compared with the placebo, in terms of acceptability, overall active comparators did not significantly decrease all-cause discontinuance rates [RR = 0.97, 95%CI (0.78, 1.20)], and the significance decreased due to AEs [RR = 2.42, 95%CI (1.41, 4.13)]. Nevertheless, overall there was no statistically significant difference for overall AEs, including somnolence, sedation, dizziness, paresthesia, anxiety, blurred vision, generalized anxiety disorder, and sleep disturbance. All funnel plots were symmetrical and no publication bias was found.

Conclusion: Active drugs, especially amitriptyline, imipramine, and quetiapine, had a positive effect on the improvement of combat-related PTSD symptoms. Despite there...
being no significant increase in the AEs of the active drugs, the fact that the discontinuation rates of these drugs, including risperidone, imipramine, and topiramate, were increased deserves attention. Furthermore, as active drugs were effective across ethnic groups and battlefields, active drug regimens were revealed to be more appropriate for treating people with symptoms of extreme severe PTSD (≥80) or PTSD that is at least 8 weeks old. In addition, current evidence was from adults under 60 years of age and male combat-related PTSD. Whether this evidence can be extended to other populations of combat-related PTSD needs to be confirmed by subsequent high-quality, large-sample studies.

Keywords: post-traumatic stress disorder, veterans, pharmacological interventions, depression, anxiety

1 INTRODUCTION

Post-traumatic stress disorder (PTSD) is a kind of stress disorder with severe clinical symptoms, poor prognosis, and possible brain damage in traumatic and stress-related disorders (Mithoefer et al., 2018). PTSD refers to individuals who have faced unusually strong mental stress, such as natural disasters, traffic accidents, the sudden loss of relatives, and other accidents, which result in the emergence of stress-related disorder. The lifetime prevalence of PTSD in adults is approximately 8% (Kessler et al., 2012; Nichter et al., 2021), between 10 and 20% of trauma survivors in some cases develop chronic PTSD. This brings considerable distress to society, families, and individuals, and causes huge economic and social burdens, and even increases the risk of suicide (Kessler et al., 1995; Kessler, 2000; Frayne et al., 2004; Krysinska and Lester, 2010; Wittchen et al., 2011).

PTSD is a common clinical mental disease, especially for some high-risk groups. In Iran, which has survived 8 years of war, about 40% of veterans with PTSD have combat-related PTSD associated with more severe symptoms and extreme symptom conditions that are harder to treat PTSD (Mithoefer et al., 2018). Current research (Mohamed and Rosenheck, 2008) indicates that medication is a common option for the treatment of combat-related PTSD. Although sertraline and paroxetine are considered important and common medications for PTSD, their actual efficacy of selective serotonin reuptake inhibitors (SSRIs) remains controversial (Bajor et al., 2011). In addition, current drug regimens for PTSD do not have satisfactory clinical outcomes, with an approximately 60% response rate among PTSD patients treated with SSRIs (Suttajit et al., 2014). Related studies (Bisson et al., 2019) have focused on the efficacy of SSRI on combat-related PTSD, investigating the anxiety and depression associated with PTSD. However, the three core symptoms, including avoidance, re-experience, and hyper-arousal, based on the DMS-III have not been researched to date (Bisson et al., 2019). Other studies have found that ketamine and other drugs can affect the pathway of specific signals in suicidal tendency treatment, which achieves the effect of rapid feelings of anti-suicide and anti-depression (De Berardis et al., 2018). However, as knowledge of neuroscience and the pathophysiology of human behavior continue to advance, suicidal behavior remains a challenge. Although the possible pathophysiological factors that may explain the complex link between PTSD and suicide have been explored in studies, there is little research on the underlying role of neurobiological factors (e.g., genetics, exogenous and endogenous stressors, epigenetic, the hypothalamic-pituitary-adrenal stress-response system, the involvement of the monoaminergic neurotransmitter systems, particularly the serotonergic ones, the lipid profile), neuro-immunological biomarkers, brain-derived neurotrophic factors, and other neuromodulators (Orsolini et al., 2020). Based on the fact that treating PTSD with conventional drugs can involve major challenges, including excessive adverse effects, limited efficacy, and lower patient compliance, this study comprehensively evaluates the efficacy, acceptability, and safety of active drugs for PTSD, and explores the influence of relevant confounding factors on PTSD to ensure the reliability and extrapolation of evidence, and provide a reference for clinicians when making treatment decisions.

2 METHODS

2.1 Search Strategy

The Ovid MEDLINE, Ovid EMBASE, Cochrane Library, Scopus, ScienceDirect, and Web of Science databases were searched for randomized controlled trials (RCTs), which had investigated active pharmaceutical administration in combat-related PTSD until April 21, 2021. The detailed search strategy is displayed in Supplementary Method S1.

2.2 Inclusion Criteria and Exclusion Criteria

The included studies met the following criteria: 1) Adult (≥18 years old) with all combat-related PTSD according to diagnostic criteria, including DSM-III, DSM-III-R, DSM-IV, DSM-IV-TR, DSM-V or ICD-10; 2) Interventions: any dosages and treatment duration of active pharmaceutical administration, including amitriptyline, aripiprazole, dexamethasone, fluoxetine, guanfacine, imipramine, olanzapine, phenelzine, prazosin, pregabalin, quetiapine, rituxol, risperidone, rivastigmin, topiramate, vilazodone, and other active drug agents; 3) Comparisons: Placebo; 4) Outcomes: effectiveness (changes in total symptoms of combat-related PTSD, depression, anxiety, re-experiencing, avoidance and hyper-arousal), acceptability [all-cause discontinuation and discontinuation due to adverse events (AEs)], and AEs (somnolence, sedation, dizziness, paresthesia, anxiety and blurred vision, generalized anxiety disorder and sleep disturbance). The change in total symptoms of combat-related PTSD according to the clinician rating scale was defined as
primary outcome, and the others were defined as secondary outcomes. 5) Study design of included studies: RCTs.

Studies with one of the following criteria were excluded: 1) subjects diagnosed with schizophrenia, schizophrenia disorder, bipolar disorder, exhibiting clinically significant suicidal, homicidal ideation or other dangers; 2) a combination of treatment options other than drug intervention; 3) duplicate data or data could not be retrieved.

2.3 Data Extraction and Quality Assessment
Basic information was extracted, including study, year, sample, age, gender, battlefield, race, diagnostic criteria, baseline score, dosages of drugs, duration of treatment, and interesting outcomes. We used the change values from the baseline as much as possible in all the continuous outcomes. If change values from the baseline were not mentioned, we used a comparison of final measurements according to the Cochrane handbook (Julian and Sally, 2011), which is a randomized trial estimating the same baseline value in theory.

The quality assessment was employed by the risk of bias based on the Cochrane Handbook for Systematic Reviews of Interventions (Julian and Sally, 2011).

2.4 Statistical Analysis
Risk ratios (RR) or standardized mean difference (SMD) with 95% were employed for dichotomous data and continuous data. The heterogeneity of the meta-analyses was measured by calculating the $I^2$ (Higgins et al., 2003). If $I^2 \geq 40\%$, the random effects models were employed; otherwise, the fixed model was adopted. Subgroup analyses were employed for investigating the clinical benefits of overall active comparators in patients of age ($< 60$ years and $\geq 60$ years), race (white and other), gender (male and female), different battlefield, duration of treatment, and severity of trauma, based on CAPS scores ($60 – 79$ and $\geq 80$) based on changes in total symptoms of combat-related PTSD, depression, and anxiety. Funnel plots were used to detect publication bias (Moher et al., 2009). All statistical analyses were employed for the software of RevMan 5.4.1. The Preferred Reporting Items of Systematic Review and Meta-Analyses (PRISMA) by systematic review and meta-analysis (Moher et al., 2009) were employed for the systematic evaluation and meta-analysis.
TABLE 1 | Summary of included clinical trials and patient characteristics.

| Study, year | Sample (I/C) | Age (SD) | Gender (male, %) | Battlefield | Race (white) | Diagnostic criteria | Baseline score | Dosages of drugs (mg/d) | During of treatment (week) |
|-------------|--------------|----------|-----------------|-------------|--------------|---------------------|---------------|------------------------|---------------------------|
| Spangler et al. (2000) | 36/38 | 37.8 (8.5) | 63 (85.1) | Afghanistan or Iraq | 47 | DSM-IV | CAPS: 70.6 (19.6) | Riluzole 100–200 mg/d | 8 |
| Akuchekian and Amanat, (2004) | 34/33 | 39.8 (4.19) | 67 (100) | Iran or Iraq | NR | DSM-IV | CAPS: 49.81 (8.42) | Topiramate 50–500 mg/d | 12 |
| Baniasadi et al. (2014) | 18/19 | 48.16 (3.55) | 37 (100) | Iran or Iraq | NR | DSM-IV-TR | PCL-M: 55.94 (7.65) | Pregabalin 75–300 mg/d | 6 |
| Bartozikis et al. (2005) | 33/32 | 51.6 (4.2) | 65 (100) | Vietnam (63), Persian Gulf (2) | 44 | DSM-IV | CAPS: 100.43 (13.96) | Risperidone 3 mg/d | 16 |
| Davidson et al. (1990) | 25/21 | 49.22 (11.94) | NR | NR | NR | DSM-III | IES: 34.54 (5.79) | Guanfacine 1–2 mg/d | 8 |
| Davis et al. (2008) | 18/17 | 53.46 (7.46) | 32 (91.43) | NR | 25 | DSM-IV | CAPS: 85.14 (17.38) | Risperidone 1–6 mg/d | 5 |
| Hamner et al. (2003) | 19/18 | 52.21 (6.44) | NR | Vietnam | 17 | DSM-IV | CAPS: 89.72 (18.31) | Fluoxetine 48 (10–60 mg/d) | 12 |
| Hertzig et al. (2000) | 6/6 | 46 (44–48) | 12 (100) | Vietnam | 5 | DSM-IV | DTS: 108.5 (20.09) | Imipramine 225 (50–300 mg/d) | 8 |
| Kosten et al. (1991) | 19/18 | 38.51 (2.04) | 37 (100) | Vietnam | 31 | DSM III | IES: 31.77 (14.21) | Fluoxetine 48 (10–60 mg/d) | 8 |
| Kosten et al. (1991) | 23/18 | 38.56 (2.04) | 41 (100) | Vietnam | 34 | DSM III | IES: 34.96 (15.26) | Imipramine 225 (50–300 mg/d) | 8 |
| Lindley et al. (2007) | 20/20 | 53.4 (0.76) | 40 (100) | Vietnam | 25 | NR | CAPS: 61.55 (17.93) | Topiramate 50–200 mg/d | 7 |
| Monnelly et al. (2003) | 7/8 | 51.35 (6.3) | 15 (100) | Vietnam (2), Gulf war (12) | NR | DSM-IV | PCL-M: 72.47 (15.37) | Fluoxetine 48 (10–60 mg/d) | 10 |
| Nayler et al. (2015) | 7/7 | 33.82 (4.81) | 9 (64.29) | NR | 7 | DSM-IV | CAPS: 86.45 (15.37) | Amantripine 160.7 (50–300 mg/d) | 8 |
| Naylor et al. (2006) | 29/34 | NR | NR | NR | NR | DSM-IV | CAPS: 68.34 (20.57) | Guanfacine 0.5–2 mg/d | 6 |
| Petrakis et al. (2016) | 50/46 | 43.97 (13.02) | 89 (92.71) | NR | 78 | DSM-IV | CAPS: 73.78 (17.77) | Prazosin 14.5 (2–16 mg/d) | 13 |
| Ramsawamy et al. (2017) | 29/30 | 32.7 (7.1) | 57 (97) | NR | 32 | DSM-IV | CAPS: 75.45 (12.98) | Vilazodone 10–40 mg/d | 12 |
| Raskind et al. (2007) | 20/20 | 26 (9) | 2 (5) | Vietnam War: 32, World War II: 2, Korean War: 3, Panama invasion: 1, First Gulf War: 1 | 26 | DSM-IV | CAPS: 77 (19.87) | Prazosin 13 (2–15 mg/d) | 8 |
| Raskind et al. (2018) | 152/152 | 51.85 (13.78) | 297 (97.7) | NR | 203 | DSM-IV | CAPS: 81.3 (16.3) | Prazosin (1–20 mg/d for men or 1–12 mg/d for women) | 10 |
| Rezaei Ardani et al. (2017) | 12/12 | 50.22 (5.66) | 24 (100) | Iran or Iraq | NR | DSM-IV-TR | PCL-M: 49.5 (5.85) | Rivastigmin 3–6 mg/d | 12 |
| Stein et al. (2002) | 10/9 | 53.26 (7.44) | 19 (100) | Vietnam (16), NR (3) | NR | DSM-IV | CAPS: 85.11 (19.03) | Olanzapine 15 (10–20 mg/d) | 8 |
| Suris et al. (2017) | 26/28 | 37.5 (14.15) | 54 (100) | NR | 36 | DSM-IV-TR | PCL: 55.85 (10.88) | Dexamethasone 0.15 mg/kg | 2 |
| Vilarreal et al. (2016) | 23/19 | 52.95 (11.07) | 75 (93.75) | NR | 42 | DSM-IV | CAPS: 73.12 (14.24) | Quetiapine 25–800 mg/d | 12 |

Note: C: placebo; CAPS: clinician-administered PTSD, scale; DSM-IV-TR: the Diagnostic and Statistical Manual of Mental Disorders, ED, 4, Text Rev; DTS: davidson trauma scale; I: active drug agent; IES-R: the Impact of Event Scale-Revised; M.I.N.I.: the Mini-International Neuropsychiatric Interview; NR: not reported; PTSD: Post-traumatic stress disorder; PCL-M: the Patient Checklist for PTSD-Military Version; SD: standard deviation; SI-PTSD: Structured Interview for Post-Traumatic Stress Disorder; SPRINT: short post traumatic stress disorder rating interview.

3 RESULTS

3.1 Study Selection

As shown in the study selection in Figure 1, 8,967 studies were searched from databases, there were 6,758 studies left after deleting duplicate studies, among which this study used titles and abstracts to filter. We excluded 6,671 studies due to them having unrelated themes. A full-text review was done for the remaining 87 studies and we identified 21 articles (Davidson et al., 1990; Kosten et al., 1991; Hertzig et al., 2000; Stein et al.,...
2002; Hamner et al., 2003; Monnelly et al., 2003; Akuchekian and Amanat, 2004; Bartozkis et al., 2005; Neylan et al., 2006; Lindley et al., 2007; Raskind et al., 2007; Davis et al., 2008; Baniasadi et al., 2014; Naylor et al., 2015; Petrakis et al., 2016; Villarreal et al., 2016; Ramaswamy et al., 2017; Rezaei Ardani et al., 2017; Suris et al., 2017; Raskind et al., 2018; Spangler et al., 2020) with 22 RCTs that meet the inclusion criteria for this meta-analysis.

### 3.2 Study Characteristics and Quality Assessment

In the meta-analysis, 22 RCTs with 1,221 patients provided an evaluation of the clinical benefit of drugs in combat-related PTSD. However, there were 12 RCTs in an all-male population (Kosten et al., 1991; Hertzberg et al., 2000; Stein et al., 2002; Monnelly et al., 2003; Bartozkis et al., 2005; Neylan et al., 2006; Raskind et al., 2007; Davis et al., 2008; Baniasadi et al., 2014; Naylor et al., 2015; Petrakis et al., 2016; Villarreal et al., 2016; Ramaswamy et al., 2017; Rezaei Ardani et al., 2017; Suris et al., 2017; Raskind et al., 2018; Spangler et al., 2020) with 22 RCTs that meet the inclusion criteria for this meta-analysis.

### 3.3 Results of Meta-Analysis

#### 3.3.1 Effectiveness

**3.3.1.1 Changes in Total Symptoms of Combat-Related PTSD**

In terms of changes in total combat-related PTSD symptoms, seven drugs in 14 RCTs were compared with the placebo in this study. Overall active comparators [SMD = −0.36, 95%CI (−0.62, −0.09)] are shown in Figure 2 and quetiapine (SMD = −0.49, 95%CI (−0.93, −0.04)) in Table 2, which showed statistical differences. However, other active drugs, including topiramate, guanfacine, prazosin, vilazodone, risperidone, and olanzapine did not significantly reduce the change in total symptoms of combat-related PTSD, as outlined in Table 2.

#### 3.3.1.2 Symptom of Depression

In terms of changes in depressive symptoms, nine drugs in 14 RCTs were compared with the placebo in this study. As shown in Figure 3, overall, the active comparators [SMD = −0.28, 95%CI (−0.45, −0.10)], both amitriptyline [SMD = −1.16, 95%CI (−1.90, −0.41)] and quetiapine [SMD = −0.63, 95%CI (−1.08, −0.18)] significantly effected improved depressive symptoms, as shown in Table 2. However, other active drugs, including risperidone, olanzapine, pregabalin, risperidone, and dexamethasone had no statistically significant difference, as shown in Table 2.

#### 3.3.1.3 Symptom of Anxiety

In terms of changes in anxiety symptoms, seven drugs in 8 RCTs were compared with placebo in this study. Overall active comparators [SMD = −0.44, 95%CI (−0.64, −0.23)] and different drugs classifications in Figure 4, such as amitriptyline [SMD = −0.82, 95%CI (−1.46, −0.17)], amitriptyline [SMD = −0.99, 95%CI (−1.72, −0.26)], and imipramine [SMD = −0.67, 95%CI (−1.34, −0.01)] significantly reduced the symptoms of anxiety. However, other active drugs, including phenelzine, quetiapine, risperidone, and pregabalin had no statistically significant difference, as shown in Table 2.

---

**FIGURE 2** | Forest for change in total symptoms of combat-related PTSD based on a clinician-assessed scale based on CAPS scores.
TABLE 2 | Meta-analysis of different drug classifications for efficacy outcomes.

| Drugs                  | N   | Sample (T/C) | SMD, 95% CI   | Drugs                  | N   | Sample (T/C) | SMD, 95% CI   |
|------------------------|-----|--------------|---------------|------------------------|-----|--------------|---------------|
| Amitriptyline          | 0   | NR           |               | Amitriptyline          | 1   | 17/16        | −1.16 (−1.90, −0.41) |
| Dexamethasone          | 0   | NR           |               | Dexamethasone          | 1   | 26/28        | −0.14 (−0.67, 0.40)  |
| Guanfacine             | 2   | 47/51        | −0.11 (−0.51, 0.29) | Guanfacine             | 1   | 18/17        | −0.32 (−0.98, 0.35)  |
| Olanzapine             | 3   | 199/197      | −0.02 (−1.13, 0.17) | Olanzapine             | 1   | 10/9         | −0.92 (−1.88, 0.04)  |
| Phenelzine             | 1   | 23/18        | −0.46 (−1.08, 0.17) | Phenelzine             | 1   | 23/18        | −0.25 (−0.87, 0.37)  |
| Quetiapine             | 1   | 42/38        | −0.49 (−0.93, −0.04) | Quetiapine             | 1   | 42/38        | −0.35 (−0.80, 0.43)  |
| Risperidone            | 0   | NR           |               | Risperidone            | 1   | 18/23        | −0.24 (−0.87, 0.37)  |
| Quetiapine             | 1   | 50/46        | −0.06 (0.09, −0.13) | Quetiapine             | 1   | 50/46        | −0.53 (−0.98, −0.09) |
| Topiramate             | 2   | 14/15        | −0.57 (−1.41, 0.28) | Topiramate             | 1   | 25/22        | −0.12 (−0.69, 0.45)  |
| Vilaizodone            | 1   | 9/15         | −0.57 (−1.41, 0.28) | Vilaizodone            | 1   | 23/24        | −0.12 (−0.69, 0.45)  |
| Avordane               | 1   | 17/16        | −0.99 (−1.72, −0.26) | Avordane               | 1   | 17/16        | −0.75 (−1.46, −0.04) |
| Imipramine             | 1   | 19/18        | −0.67 (−1.34, −0.01) | Imipramine             | 1   | 19/18        | −1.07 (−1.77, −0.38) |
| Fluoxetine             | 1   | 23/18        | −0.46 (−1.08, 0.17) | Fluoxetine             | 1   | 23/18        | −0.19 (−0.80, 0.43)  |
| Prazosin               | 1   | 18/19        | −0.26 (−0.90, 0.39) | Prazosin               | 1   | 50/46        | 0.05 (−0.35, 0.45)   |
| Quetiapine             | 1   | 12/19        | −0.41 (−0.86, 0.03) | Quetiapine             | 1   | 42/38        | −0.53 (−0.98, −0.09) |
| Riluzole               | 1   | 36/38        | −0.16 (−0.62, 0.30) | Riluzole               | 1   | NR           | −0.35 (−0.80, 0.43)  |
| Risperidone            | 0   | NR           |               | Risperidone            | 1   | 24/13        | −0.33 (−0.76, 0.11)  |
| Rivastigmme            | 1   | 18/23        | −0.82 (−1.46, −0.17) | Rivastigmme            | 1   | 15/15        | 0.03 (−0.69, 0.74)   |
| Vilaizodone            | 1   | 22/24        | −0.21 (−0.79, 0.37) | Vilaizodone            | 1   | 15/15        | 0.03 (−0.69, 0.74)   |

Note: NR, not reported; PTSD, Post-traumatic stress disorder; I, intervention; C, placebo; CI, confidence interval; N, number of included studies; SMD, standard mean difference.

FIGURE 3 | Forest for symptoms of depression.

3.3.1.4 Symptoms of Re-Experiencing
In terms of changes in the symptoms of anxiety, eight drugs in 9 RCTs were compared with placebo in this study. As shown in Figure 5, overall, active comparators [SMD = −0.33, 95% CI (−0.52, −0.13)], amitriptyline [SMD = −0.75, 95%CI (−1.46, −0.04)], imipramine [SMD = −1.07, 95%CI (−1.77, −0.38)], and quetiapine [SMD = −0.53, 95%CI (−0.98, −0.09)] had significance and effectively improved re-experiences of symptoms (Table 2). However, other active drugs, including risperidone, guanfacine, phenelzine, prazosin, and
rivastigmine had no statistically significant difference, as indicated by Table 2.

3.3.1.5 Symptoms of Avoidance
Of the eight drugs in the 9 RCTs compared with placebo in this study, overall the active comparators [SMD = −0.24, 95%CI (−0.43, −0.05)] shown in Figure 6 and different drug classifications, including amitriptyline [SMD = −0.90, 95%CI (−1.62, −0.18)] and imipramine [SMD = −0.81, 95%CI (−1.49, −0.14)], significantly reduced symptoms of avoidance (see Table 2). Other active drugs, including risperidone, guanfacine, prazosin, rivastigmine, and quetiapine showed no statistically significant difference (see Table 2).

3.3.1.6 Symptoms of Hyper-Arousal
In terms of changes in the symptoms of anxiety, five drugs in 6 RCTs were compared with placebo. The active comparators [SMD = −0.26, 95%CI (−0.48, −0.03)] outlined in Figure 7, including quetiapine [SMD = −0.55, 95%CI (−1.00, −0.10)] are shown in Table 2. Other active drugs, including risperidone, guanfacine, prazosin, and rivastigmine, had no statistically significant difference (see Table 2).

3.3.2 Acceptability
3.3.2.1 All-Cause Discontinuation
The active comparators [RR = 0.97, 95%CI (0.78, 1.20)] shown in Figure 8, except for risperidone [RR = 1.77, 95%CI (1.09,
### FIGURE 7 | Forest for symptoms of hyper-arousal.

### FIGURE 8 | Forest for all-cause discontinuation rate.

### TABLE 3 | Meta-analysis of different drug classifications for acceptability.

| Drugs          | N  | Sample (T/C) | RR, 95% CI | Discontinuation rate due to AEs |
|----------------|----|--------------|------------|-------------------------------|
| Amtriptyline   | 1  | 25/21        | 1.34 (0.52, 3.49) | Amtriptyline                  |
| Aripiprazole   | 1  | 7/7          | 5.00 (0.28, 88.53) | Aripiprazole                  |
| Dexamethasone  | 0  | NR           | NR         | Dexamethasone                  |
| Fluoxetine     | 1  | 6/6          | 3.00 (0.15, 61.74) | Fluoxetine                     |
| Guanfacine     | 2  | 47/51        | 2.15 (0.79, 5.82) | Guanfacine                     |
| Imipramine     | 1  | 19/18        | 0.32 (0.12, 0.80) | Imipramine                     |
| Olanzapine     | 1  | 10/9         | 1.35 (0.29, 6.34) | Olanzapine                     |
| Phenelzine     | 1  | 23/18        | 0.78 (0.47, 1.30) | Phenelzine                     |
| Prazosin       | 3  | 222/218      | 0.83 (0.52, 1.31) | Prazosin                       |
| Pregabalin     | 1  | 18/19        | Not estimable   | Pregabalin                     |
| Quetiapine     | 1  | 40/38        | 0.59 (0.34, 1.01) | Quetiapine                     |
| Riluzole       | 1  | 36/38        | 1.76 (0.45, 6.83) | Riluzole                       |
| Risperidone    | 3  | 72/70        | 1.77 (1.09, 2.89) | Risperidone                    |
| Rivastigmin    | 0  | NR           | NR          | Rivastigmin                    |
| Topiramate     | 2  | 57/51        | 0.76 (0.45, 1.27) | Topiramate                     |
| Valprozide     | 1  | 29/30        | 0.52 (0.15, 1.53) | Valprozide                     |

**Note:** NR, not reported; T, intervention; C, placebo; CI, confidence interval; N, number of included studies; RR, relative risk.
2.89] and imipramine [RR = 0.32, 95% CI (0.12, 0.80)] did not show a statistically significant difference for all-cause discontinuation, as indicated by Table 3.

### 3.3.2 Discontinuation due to AEs

The difference in the overall active comparators [RR = 2.42, 95% CI (1.41, 4.13)] discontinued due to AEs was statistically significant compared with placebo, see Figure 9. As Table 3 reveals, of the different drug classifications discontinued due to AEs, topiramate [RR = 4.17, 95% CI (1.15, 15.13)] was significantly higher than placebo, but the other active comparators were not.

### 3.3.3 Adverse Events

Compared with placebo, overall, there was no statistically significant difference among active comparators in all AEs, including somnolence [RR = 4.55, 95% CI (0.25, 8.70)], sedation [RR = 5.00, 95% CI (0.26, 98.00)], dizziness [RR = 1.98, 95% CI (0.91, 4.31)], paresthesia [RR = 3.00, 95% CI (0.31, 69.52)], anxiety and blurred vision [RR = 0.33, 95% CI (0.01, 7.72)], generalized anxiety disorder [RR = 0.98, 95% CI (0.47, 2.04)], and sleep disturbance [RR = 1.50, 95% CI (0.28, 8.04)] in Table 4.

### 3.3.4 Stratified Analyses

#### 3.3.4.1 Different Ages

A pooling analysis of studies involving the effect of drugs on combat-related PTSD of different ages (18–60 and more than 60) showed that overall active comparators [SMD = −0.36, 95% CI (−0.62, −0.09)] can lower the changes in combat-related PTSD symptoms, depressive [SMD = −0.28, 95% CI (−0.45, −0.10)] and anxiety [SMD = −0.44, 95% CI (−0.64, −0.23)], as shown in Table 5. However, there were no patients over the age of 60 years in the RCTs.

#### 3.3.4.2 Different Races

Compared with placebo, overall active comparators did significantly reduce the change in total symptoms of combat-related PTSD in study participants of white [SMD = −0.63, 95% CI (−1.08, −0.18)] and other races [SMD = −0.34, 95% CI (−0.63, −0.06)]. Moreover, compared with placebo for depressive symptoms, overall active comparators had significant statistical differences in participants of white [SMD = −0.41, 95% CI (−0.86, 0.03)] and participants of other races [SMD = −0.21, 95% CI (−0.40, −0.03)]. Overall active comparators in white [SMD = −0.41, 95% CI (−0.86, 0.03)] and participants of other races in Table 5.

#### 3.3.4.3 Different Gender

Treatment of overall active comparators [SMD = −0.74, 95% CI (−1.37, −0.12)] significantly reduced the change in total symptoms of combat-related PTSD for male adults. Furthermore, overall active
TABLE 5 | Stratified analyses for the change in total symptoms of combat-related PTSD, depression, and anxiety.

| Stratified analyses       | Change in total symptoms of combat-related PTSD | Depression | Anxiety |
|---------------------------|-----------------------------------------------|------------|---------|
|                           | N     | Sample (T/C) | SMD, 95%CI | N     | Sample (T/C) | SMD, 95%CI | N     | Sample (T/C) | SMD, 95%CI |
| Different age             |       |             |            |       |             |            |       |             |            |
| 18–60                     | 14    | 430/430     | −0.36 (−0.62, −0.09) | 14    | 266/274     | −0.28 (−0.45, −0.10) | 8     | 195/194     | −0.44 (−0.64, −0.23) |
| >60                       | 0     | 0           | NR          | 0     | 0           | NR          | 0     | 0           | NR          |
| Different age             |       |             |            |       |             |            |       |             |            |
| White                     | 1     | 42/38       | −0.49 (−0.93, −0.04) | 1     | 42/38       | −0.63 (−1.08, −0.18) | 1     | 42/38       | −0.41 (−0.86, 0.03)  |
| Other                     | 13    | 368/392     | −0.34 (−0.63, −0.06) | 13    | 224/236     | −0.21 (−0.40, −0.03) | 13    | 153/156     | −0.44 (−0.67, −0.22) |
| Different gender          |       |             |            |       |             |            |       |             |            |
| Male                      | 5     | 81/88       | −0.74 (−1.37, −0.12) | 7     | 123/130     | −0.18 (−0.44, 0.07)  | 4     | 78/88       | −0.55 (−0.87, −0.23) |
| Female                    | 0     | NR          | NR          | 0     | NR          | NR          | 0     | NR          | NR          |
| Different battlefield     |       |             |            |       |             |            |       |             |            |
| Afghanistan or Iraq war   | 0     | NR          | NR          | 1     | 36/38       | 0.03 (−0.42, 0.49)  | 1     | 36/38       | −0.16 (−0.62, 0.30) |
| Iran or Iraq war          | 1     | 34/33       | −1.61 (−2.17, −1.06) | 1     | 18/19       | 0.22 (−0.43, 0.86)  | 1     | 18/19       | −0.26 (−0.90, 0.39) |
| Vietnam war               | 3     | 34/39       | −0.04 (−0.58, 0.49) | 3     | 51/51       | −0.17 (−0.56, 0.23) | 2     | 42/36       | −0.56 (−1.01, −0.10) |
| Other                     | 11    | 368/364     | −0.17 (−0.31, −0.02) | 19    | 197/204     | −0.32 (−0.53, −0.10) | 4     | 99/101      | −0.55 (−0.87, −0.22) |
| Duration of Treatment     |       |             |            |       |             |            |       |             |            |
| ≤8 weeks                  | 5     | 92/100      | −0.21 (−0.50, 0.08) | 11    | 219/227     | −0.23 (−0.46, 0.01) | 5     | 113/109     | −0.44 (−0.72, −0.15) |
| >8 weeks                  | 9     | 338/330     | −0.27 (−0.42, −0.11) | 3     | 83/85       | −0.31 (−0.73, 0.11) | 3     | 82/85       | −0.46 (−0.76, −0.14) |
| Severity of Trauma Based on CAPS Scores |       |             |            |       |             |            |       |             |            |
| Severe PTSD symptoms (60–79) | 6     | 160/170    | −0.20 (−0.42, 0.01) | 6     | 135/164     | −0.13 (−0.40, 0.14) | 3     | 100/100     | −0.27 (−0.55, 0.01) |
| Extreme severe PTSD symptoms (≥80) | 5     | 204/205    | −0.12 (−0.31, 0.08) | 4     | 60/64       | −0.40 (−0.76, −0.04) | 1     | 18/23       | −0.82 (−1.46, −0.17) |

Note: NR, not reported; T, intervention; C, placebo; CI, confidence interval; N, number of included studies; SMD, standard mean difference.

Comparators [SMD = −0.18, 95%CI (−0.44, 0.07)] did not significantly relieve depressive symptoms. However, overall, active comparators [SMD = −0.55, 95%CI (−0.87, −0.23)] had significant therapeutic effects for anxiety in Table 5. Unfortunately, no RCT for female participants was involved in the systematic evaluation and meta-analysis, there was no evidence of drug treatment in female participants with combat-related PTSD.

3.3.4.4 Different Battlefield

Based on various battlefields, the change in total symptoms of combat-related PTSD compared with placebo showed that overall, active comparators for various battlefields, including the Iraq or Iran war [SMD = −1.61, 95%CI (−2.17, −1.06)] and unknown battlefields [SMD = −0.17, 95%CI (−0.31, −0.02)], could significantly lower the changes in total symptoms of combat-related PTSD, but for Vietnam war battlefields [SMD = −0.04, 95%CI (−0.58, 0.49)] there was no relief of the change in total symptoms of combat-related PTSD. Based on various battlefields, depression compared with placebo indicated comparative battlefields which had no significant difference for depression, including Afghanistan or Iraq [SMD = 0.03, 95%CI (−0.42, 0.49)], Iraq or Iran [SMD = 0.22, 95%CI (−0.43, 0.86)], and the Vietnam war [SMD = −0.17, 95%CI (−0.56, 0.23)], but overall, active comparators for unknown battlefields [SMD = −0.32, 95%CI (−0.53, −0.10)] could relieve depression. In terms of anxiety, compared with placebo the overall active comparators for various battlefields, including Afghanistan or Iraq [SMD = −0.16, 95%CI (−0.62, 0.30)] and Iraq-Iran [SMD = −0.26, 95%CI (−0.90, 0.39)], had no significant statistical difference, but overall active comparators for the Vietnam war [SMD = −0.56, 95%CI (−1.01, −0.10)] and unknown battlefields [SMD = −0.55, 95%CI (−0.87, −0.22)] showed improved anxiety, see Table 5.

3.3.4.5 Duration of Treatment

Compared with placebo, overall active comparators for a duration of treatment of less than 8 weeks [SMD = −0.21, 95%CI (−0.50, 0.08)] did not significantly lower changes to total symptoms of combat-related PTSD. However, overall active comparators [SMD = −0.27, 95%CI (−0.42, −0.11)] in the duration of drug of more than 8 weeks can significantly lower the change in total symptoms of combat-related PTSD. Furthermore, Compared with placebo for depressive, overall active comparators of less than 8 weeks [SMD = −0.55, 95%CI (−0.87, −0.23)] did not significantly relieve depressive symptoms. However, overall active comparators of less than 8 weeks [SMD = −0.56, 95%CI (−1.01, −0.10)] and unknown battlefields [SMD = −0.55, 95%CI (−0.87, −0.22)] showed improved anxiety, see Table 5.
3.3.4.6 Severity of Trauma

Overall active comparators in severe PTSD symptoms (60–79) [SMD = –0.20, 95%CI (–0.42, 0.01)] and extremely severe PTSD symptoms (≥80) [SMD = –0.12, 95%CI (–0.31, 0.08)] had not significantly lowered the change in total symptoms of combat-related PTSD. Moreover, compared with placebo in depression, overall active comparators in severe PTSD symptoms (60–79) [SMD = –0.13, 95%CI (–0.40, 0.14)] did not show significant improvement, but overall active comparators with extreme severe PTSD symptoms (≥80) [SMD = –0.40, 95%CI (–0.76, –0.04)] can improve depression. Compared with placebo, overall active comparators in severe PTSD symptoms (60–79) [SMD = –0.27, 95%CI (–0.55, 0.01)] did not significantly improve anxiety, but overall active comparators with extreme severe PTSD symptoms (≥80) [SMD = –0.82, 95%CI (–1.46, –0.17)] can relieve anxiety, as shown in Table 5.

3.4 Publication Bias

All funnel plots were symmetrical and no publication bias was found, as indicated in Supplemental Figures 1–8.

4 DISCUSSION

A total of 1,263 populations of combat-related PTSD participated in 22 RCTs were included in our evaluation of the clinical benefit of drugs in treating combat-related PTSD. Studies investigating the correlation of the different underlying factors of PTSD have found that the symptomatic characteristics of anxiety and depression appeared to be more closely related to factors reflecting general anxiety than to more specific aspects of PTSD that reflect re-experience, avoidance, and hyper-arousal. This study found that guanfacine and quetiapine improved depressive symptoms positively, while risperidone, amitriptyline, and imipramine had positive effects on anxiety. Guanfacine is also an α2-adrenoreceptor agonist commonly used to treat high blood pressure and attention deficit hyperactivity disorder. However, the nightmares and sleep disturbances caused by traumatic episodes can also benefit. Because of its long half-life, it was more popular than the other adrenergic drugs mentioned above. Quetiapine’s properties as a partial agonist of 5-HT1A and as a potent inhibitor of norepinephrine transporter through its metabolite seem to partly explain the mechanism of major depressive disorder treatment (Cross et al., 2016). The receptor binding properties of quetiapine were complex and it seems impossible to explain the effects observed in major depression and anxiety disorders by a single mechanism. In addition, the amitriptyline, imipramine, and quetiapine can effectively relieve the re-experiencing symptoms. The amitriptyline and quetiapine had good clinical benefits for avoidance, and the quetiapine had a good therapeutic effect on hyper-arousal symptoms. It is important to note that quetiapine is effective against bipolar depression (Suttajit et al., 2014), and the present study speculates that this may be one of the reasons why quetiapine was effective depressive symptoms. Furthermore, TCAs, including amitriptyline and imipramine, were absorbed rapidly and distributed in large quantities, and its elimination can be delayed for 10 days (Abdollahi and Mostafalou, 2014). They acted as catecholamines reuptake inhibitors, including serotonin and norepinephrine, but they also had anticholinergic, antihistamine, and quinine effects. It is worth noting that cardiotoxicity was the main adverse effect of excessive use of TCAs, and sodium bicarbonate was used to treat poisoning. This was different from other studies (Puetz et al., 2015) that looked at medications for anxiety and depression, in which treatment with SSRIs and TCAs have been found to reduce PTSD, anxiety, and depression symptoms in veterans. SSRIs also play a role in the symptom improvement of PTSD, which was derived from the mechanism that SSRIs were neurotransmitters were released by synaptic vesicles in neurons and act on postsynaptic neurons. Neurotransmitter release was quantum release, synaptic vesicles were not released one by one, nor were they released in groups, they were released all at once and hydrolyzed rapidly. When released, it acted on the postsynaptic membrane, causing the next neuron to fire. The simplest way to do this was to reabsorb the neurotransmitters that were released, which is how neurotransmitters reabsorb. SSRIs drugs acted on the reabsorption process to prevent its reuptake and continue to act on postsynaptic neurons to increase the concentration of SSRIs in the synaptic cleft, thus playing a role of anti-depression and anti-anxiety.

NICE Guidelines recommend the use of antipsychotics for people with PTSD (Excellence NIfHaC, 2019). PTSD comorbidities (McCaughey et al., 2012) are treated differently for non-veterans, with higher rates of suicide attempts and poorer treatment adherence (McCaughey et al., 2012; Reisman, 2016). Therefore, atypical antipsychotics may be considered more appropriate for this particular group of veterans than SSRIs. The results of the meta-analysis suggested that atypical antipsychotics improved the treatment of combat-related PTSD. This finding differs from a recent meta-analysis of the effects of drugs on PTSD. This study found that risperidone and olanzapine (Stein et al., 2002; Bartzkis et al., 2005) were suitable for veterans with extremely severe symptoms of PTSD, while there were no effective medications for veterans with severe PTSD.

In this meta-analysis, age and race were used as influencing factors for drug treatment of combat-related PTSD. In this study, drugs showed a good therapeutic effect on veterans between 18 and 60 years old, but evidence on veterans over 60 years old was lacking. The main cause appears to be women’s reported lower levels of military readiness, weaker unit cohesion, and higher incidences of depressive symptoms (Bisson et al., 2019). Unfortunately, no studies reported the treatment of female participants with drugs. In addition, the study found that anxiety can be effectively reduced in veterans when they receive medication in an unknown battlefield setting, as did those with anxiety who served in Vietnam (VA/DOD, 2018). However, overall, active comparators were not effective at treating anxiety symptoms experienced by veterans of the war in Afghanistan and Iraq, or Iran and Iraq.

Considering the efficacy of different durations of treatment, long-term treatment interventions had a more significant effect on change in total symptoms of combat-related PTSD and could reduce the clinical effect of change in total PTSD symptoms.
symptoms of combat-related PTSD. However, the duration of intervention showed no clinical advantage in improving depression. In contrast, interventions of different duration did not affect the overall outcome of anxiety and all reduced anxiety symptoms. In addition to cumulative therapeutic efficacy, the differences in duration of treatment may also be related to the low sample size allocation caused by stratified analysis, which reduces the power of statistical efficacy in each subgroup. Although many factors can influence the outcome to benefit analysis, the present study recommends that clinicians continue treatment for at least 8 weeks to better manage symptoms associated with PTSD.

Imipramine was the only drug that proved to be significantly superior in terms of the rate of discontinuation for all causes (Kosten et al., 1991). Imipramine is a tricyclic antidepressant, mainly used for the treatment of major depression, obsessive-compulsive disorder, generalized anxiety disorder, and other psychiatric disorders, which may be one of the reasons for the low withdrawal rate of imipramine due to AEs (Dean, 2012). After subgroup analysis, a study by Bartzokis, Hamner, and Monnelly showed a high effect on the all-cause discontinuation rate of risperidone (Hamner et al., 2003; Monnelly et al., 2003; Bartzokis et al., 2005). The high rate of risperidone withdrawal may be related to the dosage of risperidone. In related studies, risperidone was used in small doses with fewer side effects (Monnelly et al., 2003). In addition, the number of discontinuation due to AEs of anticonvulsive drugs increased significantly. This study also found that overall active comparators had certain AEs, including drowsiness, sedation, dizziness, paresthesias, anxiety and blurred vision, generalized anxiety disorder, and sleep disturbances. Lethargy, dizziness, sedation, and other AEs that occur from the use of quetiapine, and these AEs were paid attention to by clinicians.

Based on current guidelines and evidence, this study aims to make the following recommendations for clinicians when conducting research on combat-related PTSD. Clinicians should fully consider individual factors, including different symptoms, different populations groups, or severe sub-symptoms, when choosing drugs. Clinicians can also use the results of this study to initially identify appropriate drug treatment regimens, taking into account patients' preferences (McHugh et al., 2013; Zoellner et al., 2019). For future research, the pharmacological treatment of PTSD may need to be studied with specific drugs that have shown strong therapeutic value in small sample studies. Future studies should continue to look at this particular population of combat-related PTSD and provide a rigorous stratified analysis of baseline symptoms to identify individual differences between medications.

This study has the following limitations. First of all, despite the large number of active drugs included, the sample size of included active drugs was too small, which may lead to the low statistical power of the results in this study. Therefore, the conclusions of this study need to be verified by larger samples and high-quality RCTs in the future. Secondly, there were differences in the use of certain dosages of active drugs, which causes heterogeneity in the results and influences the accuracy of the results to some extent. Finally, the SD of continuous outcomes was missing and unavailable, which was also one of the reasons that the number of studies in this analysis was too small and affected the results.

5 CONCLUSION

Active drugs, especially amitriptyline, imipramine, and quetiapine, had a positive effect and improved combat-related PTSD symptoms. Even though there was no significant increase in AEs of the active drugs, the fact that the discontinuation rates of these drugs, including risperidone, imipramine, and topiramate, were increased still deserves attention. Furthermore, active drugs were effective across ethnic groups and battlefields, and active drug regimens were more appropriate for treating people with symptoms of extreme severe PTSD (≥80) or at least 8 weeks old. In addition, the current evidence was only from male adults under 60 years of age experiencing combat-related PTSD, whether this evidence can be extended to other populations with combat-related PTSD needs to be confirmed by subsequent high-quality, large-sample studies.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

CZ and Q-QG conceptualized and coordinated the study. CZ developed the search strategy. J-ZY, Q-QG, J-LL, and X-ZL screened citations and assessed studies for eligibility. J-LL and X-ZL extracted data. Z-XZ and R-BL performed quality assessments. J-LL and CZ performed statistical analyses. J-ZY, CZ, and Q-QG provided methodologic expertise in knowledge synthesis and resolved disagreements regarding study eligibility or quality assessments. CZ and J-ZY critically reviewed the manuscript for important intellectual content. All of the authors gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.805354/full#supplementary-material
REFERENCES

Abdollahi, M., and Mostafalou, S. (2014). Tricyclic Antidepressants in Encyclopaedia of Toxicology. Third Edition, 838–845. doi:10.1016/B978-0-12-386454-3-00796-x

Akuchekian, S., and Amanat, S. (2004). The Comparison of Topiramate and Placebo in the Treatment of Posttraumatic Stress Disorder: A Randomized, Double-Blind Study. J. Res. Med. Sci. 5, 240–244. doi:10.1184/1744-859X-5-s1-225

Bajor, L. A., Ticlea, A. N., and Osser, D. N. (2011). The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an Update on Posttraumatic Stress Disorder. Harv. Rev. Psychiatry 19, 240–258. doi:10.3109/10673229.2011.614483

Baniassadi, M., Hosseini, G., Fayazi Bordbar, M. R., Rezaei Ardani, A., and Mostafavi Torogh, H. (2014). Effect of Pregabalin Augmentation in Treatment of Patients with Combat-Related Chronic Posttraumatic Stress Disorder: a Randomized Controlled Trial. J. Psychiatr. Pract. 20, 419–427. doi:10.1097/01.jpa.0000456590.12998.41

Bartzokis, G., Lu, P. H., Turner, J., Mintz, J., and Saunders, C. S. (2005). Adjunctive Risperidone in the Treatment of Chronic Combat-Related Posttraumatic Stress Disorder. Biol. Psychiatry 57, 474–479. doi:10.1016/j.biopsych.2004.11.039

Bisson, J. I., Berliner, L., Ciotte, M., Forbes, D., Jensen, T. K., Lewis, C., et al. (2019). The International Society for Traumatic Stress Studies New Guidelines for the Prevention and Treatment of Trauma-Related Disorders: Methodology and Development Process. J. Trauma Stress 32, 475–483. doi:10.1002/its.22421

Cross, A. J., Widowoski, D., Maciag, C., Zacco, A., Hudzik, T., Liu, J., et al. (2016). Quitapine and its Metabolite Norquitapine: Translation from In Vitro Pharmacology to In Vivo Efficacy in Rodent Models. Br. J. Pharmacol. 173, 135–166. doi:10.1111/bph.13346

Davidson, J., Kudler, H., Smith, R., Mahoney, S. L., Lipper, S., Hammett, E., et al. (1990). Treatment of Posttraumatic Stress Disorder with Amitriptyline and Placebo. Arch. Gen. Psychiatry 47, 259–266. doi:10.1001/1990.0180150059010

Davis, L. L., Ward, C., Rasmussen, A., Newell, J. M., Frazier, E., and Southwick, S. M. (2008). A Placebo-Controlled Trial of Guanfacine for the Treatment of Posttraumatic Stress Disorder in Veterans. Psychopharmacol. Bull. 41, 8–18.

De Berardis, D., Fornaro, M., Valchera, A., Cavuto, M., Perna, G., Di Nicola, M., et al. (2018). Eradicating Suicide at its Roots: Preclinical Bases and Clinical Advantages in Assessment and Treatment. J. Psychiatr. Pract. 24, 178–186. doi:10.1176/appi.jcpp.20m13714

Dean, L., Arana, G. W. (2003). Adjunctive Risperidone Treatment in post-traumatic Stress Disorder. Int. Clin. Psychopharmacol. 18, 1–8. doi:10.1097/01.mp.0000063191.83096.7e

Dean, L., Arana, G. W. (2003). Adjunctive Risperidone Treatment in Post-traumatic Stress Disorder: A Preliminary Controlled Trial of Effects on Comorbid Psychotic Symptoms. Int. Clin. Psychopharmacol. 18, 1–8. doi:10.1097/00004850-200301000-00001

Dean, L., Arana, G. W. (2003). Adjunctive Risperidone Treatment in Post-traumatic Stress Disorder: A Preliminary Controlled Trial of Effects on Comorbid Psychotic Symptoms. Int. Clin. Psychopharmacol. 18, 1–8. doi:10.1097/00004850-200301000-00001

Dean, L., Arana, G. W. (2003). Adjunctive Risperidone Treatment in Post-traumatic Stress Disorder: A Preliminary Controlled Trial of Effects on Comorbid Psychotic Symptoms. Int. Clin. Psychopharmacol. 18, 1–8. doi:10.1097/00004850-200301000-00001

Dean, L., Arana, G. W. (2003). Adjunctive Risperidone Treatment in Post-traumatic Stress Disorder: A Preliminary Controlled Trial of Effects on Comorbid Psychotic Symptoms. Int. Clin. Psychopharmacol. 18, 1–8. doi:10.1097/00004850-200301000-00001
Raskind, M. A., Peskind, E. R., Chow, B., Harris, C., Davis-Karim, A., Holmes, H. A., et al. (2018). Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. *N. Engl. J. Med.* 378, 507–517. doi:10.1056/NEJMoa1507598

Raskind, M. A., Peskind, E. R., Hoff, D. J., Hart, K. L., Holmes, H. A., Warren, D., et al. (2007). A Parallel Group Placebo Controlled Study of Prazosin for Trauma Nightmares and Sleep Disturbance in Combat Veterans with Post-traumatic Stress Disorder. *Biol. Psychiatry* 61, 928–934. doi:10.1016/j.biopsych.2006.06.032

Reisman, M. (2016). PTSD Treatment for Veterans: What’s Working, What’s New, and What’s Next. *PT* 41, 623–634.

Rezaei Ardani, A., Hosseini, G., Fayyazi Bordbar, M. R., Talaei, A., and Mostafavi Toroghli, H. (2017). Effect of Rivastigmine Augmentation in Treatment of Male Patients with Combat-Related Chronic Posttraumatic Stress Disorder: A Randomized Controlled Trial. *J. Clin. Psychopharmacol.* 37, 54–60. doi:10.1097/JCP.0000000000000624

Spangler, P. T., West, J. C., Dempsey, C. L., Possemato, K., Bartolanzo, D., Aliaga, P., et al. (2020). Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms. *J. Clin. Psychiatry* 81, 20m13233. doi:10.4088/JCP.20m13233

Stein, M. B., Kline, N. A., and Matloff, J. L. (2002). Adjunctive Olanzapine for SSRI-Resistant Combat-Related PTSD: a Double-Blind, Placebo-Controlled Study. *Am. J. Psychiatry* 159, 1777–1779. doi:10.1176/appi.ajp.159.10.1777

Suris, A., Holliday, R., Adinoff, B., Holder, N., and North, C. S. (2017). Facilitating Fear-Based Memory Extinction with Dexamethasone: A Randomized Controlled Trial in Male Veterans with Combat-Related PTSD. *Psychiatry* 80, 399–410. doi:10.1080/00332747.2017.1286892

Suttajit, S., Siriruapanont, M., Maneeton, N., and Maneeton, B. (2014). Quetiapine for Acute Bipolar Depression: a Systematic Review and Meta-Analysis. *Drug Des. Devel. Ther.* 8, 827–838. doi:10.2147/DDDT.S63779

VA/DOD (2018). VA/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder: Clinician Summary. *Focus (American Psychiatric Publishing)* 16, 430–448. doi:10.1176/appi.focus.16408

Villarreal, G., Hamner, M. B., Cañive, J. M., Robert, S., Calais, L. A., Durklaski, V., et al. (2016). Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. *Am. J. Psychiatry* 173, 1205–1212. doi:10.1176/appi.ajp.2016.15070967

Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jonsson, B., et al. (2011). The Size and burden of Mental Disorders and Other Disorders of the Brain in Europe 2010. *Eur. Neuropsychopharmacol.* 21, 655–679. doi:10.1016/j.euroneuro.2011.07.018

Zoellner, L. A., Roy-Byrne, P. P., Mavissakalian, M., and Feeny, N. C. (2019). Doubly Randomized Preference Trial of Prolonged Exposure versus Sertraline for Treatment of PTSD. *Am. J. Psychiatry* 176, 287–296. doi:10.1176/appi.ajp.2018.17090995

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yan, Liu, Li, Zhang, Liu, Zhang and Gong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.